Drug and gene targeting to the brain via blood-brain barrier receptor-mediated transport systems

International Congress Series

Volumn 1277, Issue , 2005, Pages 49-62

  Pardridge, William M ^a  

^a Department of Medicine ^*  (United States)

Author keywords

Blood brain barrier; Insulin receptor; RNA interference; Transcytosis

Indexed keywords

EID: 33646461041     PISSN: 05315131     EISSN: None     Source Type: Book Series    
DOI: 10.1016/j.ics.2005.02.011     Document Type: Article

References (27)

1. Pardridge W.M. Brain drug targeting; the future of brain drug development (2001), Cambridge University Press, Cambridge
2. Suzuki Y., et al. Characterization of the relaxant effects of vasoactive intestinal peptide (VIP) and PHI on isolated brain arteries. Brain Res. 322 1 (1984) 9-16
3. McCulloch J., and Edvinsson L. Cerebral circulatory and metabolic effects of vasoactive intestinal polypeptide. Am. J. Physiol. 238 4 (1980) H449-H456
4. Wu D., and Pardridge W.M. Central nervous system pharmacologic effect in conscious rats after intravenous injection of a biotinylated vasoactive intestinal peptide analog coupled to a blood-brain barrier drug delivery system. J. Pharmacol. Exp. Ther. 279 1 (1996) 77-83
5. Sakane T., and Pardridge W.M. Carboxyl-directed pegylation of brain-derived neurotrophic factor markedly reduces systemic clearance with minimal loss of biologic activity. Pharm. Res. 14 8 (1997) 1085-1091
6. Rosenberg M.B., Hawrot E., and Breakefield X.O. Receptor binding activities of biotinylated derivatives of beta-nerve growth factor. J. Neurochem. 46 2 (1986) 641-648
7. Wu D., and Pardridge W.M. Neuroprotection with noninvasive neurotrophin delivery to the brain. Proc. Natl. Acad. Sci. U. S. A. 96 1 (1999) 254-259
8. Zhang Y., and Pardridge W.M. Conjugation of brain-derived neurotrophic factor to a blood-brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin. Brain Res. 889 1-2 (2001) 49-56
9. Zhang Y., and Pardridge W.M. Neuroprotection in transient focal brain ischemia after delayed intravenous administration of brain-derived neurotrophic factor conjugated to a blood-brain barrier drug targeting system. Stroke 32 6 (2001) 1378-1384
10. Fisher M., et al. Delayed treatment with intravenous basic fibroblast growth factor reduces infarct size following permanent focal cerebral ischemia in rats. J. Cereb. Blood Flow Metab. 15 6 (1995) 953-959
11. Belayev L., et al. Quantitative evaluation of blood-brain barrier permeability following middle cerebral artery occlusion in rats. Brain Res. 739 1-2 (1996) 88-96
12. Song B.W., et al. Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood-brain barrier delivery vector. J. Pharmacol. Exp. Ther. 301 2 (2002) 605-610
13. Deguchi Y., et al. Blood-brain barrier transport of 125I-labeled basic fibroblast growth factor. Pharm. Res. 17 1 (2000) 63-69
14. Wu D., et al. Pharmacokinetics and brain uptake of biotinylated basic fibroblast growth factor conjugated to a blood-brain barrier drug delivery system. J. Drug Target. 10 3 (2002) 239-245
15. Fiblast Safety Study Group. Clinical safety trial of intravenous basic fibroblast growth factor (bFGF, Fiblast) in acute stroke (Abstract). Stroke 29 (1998) 287
16. Zhang R.D., et al. Differential permeability of the blood-brain barrier in experimental brain metastases produced by human neoplasms implanted into nude mice. Am. J. Pathol. 141 (1992) 115-124
17. Kurihara A., Deguchi Y., and Pardridge W.M. Epidermal growth factor radiopharmaceuticals: 111In chelation, conjugation to a blood-brain barrier delivery vector via a biotin-polyethylene linker, pharmacokinetics, and in vivo imaging of experimental brain tumors. Bioconjug. Chem. 10 3 (1999) 502-511
18. Kurihara A., and Pardridge W.M. Imaging brain tumors by targeting peptide radiopharmaceuticals through the blood-brain barrier. Cancer Res. 59 24 (1999) 6159-6163
19. Pardridge W.M., Boado R.J., and Kang Y.S. Vector-mediated delivery of a polyamide ("peptide") nucleic acid analogue through the blood-brain barrier in vivo. Proc. Natl. Acad. Sci. U. S. A. 92 12 (1995) 5592-5596
20. Suzuki T., et al. Imaging endogenous gene expression in brain cancer in vivo with [111In]-peptide nucleic acid antisense radiopharmaceuticals and brain drug targeting technology. J. Nucl. Med. 45 10 (2004) 1766-1775
21. Pardridge W.M. Drug and gene targeting to the brain with molecular Trojan horses. Nat. Rev., Drug Discov. 1 2 (2002) 131-139
22. Zhang Y., et al. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental Parkinsonism. Hum. Gene Ther. 14 1 (2003) 1-12
23. Zhang Y., et al. Receptor-mediated delivery of an antisense gene to human brain cancer cells. J. Gene Med. 4 2 (2002) 183-194
24. Zhang Y., et al. Organ-specific gene expression in the rhesus monkey eye following intravenous non-viral gene transfer. Mol. Vis. 9 (2003) 465-472
25. Zhang Y., et al. Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental Parkinsonism with intravenous nonviral gene therapy and a brain-specific promoter. Hum. Gene Ther. 15 4 (2004) 339-350
26. McManus M.T., and Sharp P.A. Gene silencing in mammals by small interfering RNAs. Nat. Rev., Genet. 3 10 (2002) 737-747
27. Zhang Y., et al. Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. Clin. Cancer Res. 10 11 (2004) 3667-3677